KB-1081

LY3361237-hIgG4-S228P

Home » Antibody » LY3361237-hIgG4-S228P

Background

BTLA, a member of the immunoglobulin superfamily, has been detected on various immune cells including B and T lymphocytes, macrophages, dendritic cells and natural killer cells and interacts with herpesvirus-entry mediator (HVEM) which is also widely expressed on hematopoietic cells. LY3361237 is the first antibody drug that is known to increase the activity of BTLA to inhibit the immune system, which means it has extraordinary potential as a therapy for autoimmune diseases

Specifications

Catalog Number:
KB-1081
Cell Line Name:
LY3361237-hIgG4-S228P
Price:
0
Host Cell Line:
EXPI-CHO
Target:
BTLA
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Zhang Z, Xu X, Lu J, Zhang S, Gu L, Fu J, Jin L, Li H, Zhao M, Zhang J, Wu H, Su L, Fu YX, Wang FS. B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. J Infect Dis. 2011 Jun 1;203(11):1668-78.
Please enable JavaScript in your browser to complete this form.